Compare BA & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BA | BMY |
|---|---|---|
| Founded | 1916 | 1887 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.9B | 127.0B |
| IPO Year | 2006 | 2006 |
| Metric | BA | BMY |
|---|---|---|
| Price | $156.00 | $58.83 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 27 | 28 |
| Target Price | ★ $233.35 | $65.25 |
| AVG Volume (30 Days) | ★ 9.1M | 9.0M |
| Earning Date | 10-27-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 4.32% |
| EPS Growth | 113.51 | ★ 178.46 |
| EPS | N/A | ★ 3.98 |
| Revenue | ★ $89,463,000,000.00 | $48,194,000,000.00 |
| Revenue This Year | $8.18 | $4.23 |
| Revenue Next Year | $12.98 | N/A |
| P/E Ratio | ★ N/A | $14.66 |
| Revenue Growth | ★ 34.50 | N/A |
| 52 Week Low | $158.92 | $47.58 |
| 52 Week High | $254.35 | $68.64 |
| Indicator | BA | BMY |
|---|---|---|
| Relative Strength Index (RSI) | 23.91 | 39.40 |
| Support Level | N/A | $55.66 |
| Resistance Level | $233.91 | $60.93 |
| Average True Range (ATR) | 4.85 | 1.71 |
| MACD | -0.83 | -0.46 |
| Stochastic Oscillator | 3.22 | 13.93 |
Boeing is a major aerospace and defense firm operating in three segments: commercial airplanes; defense, space, and security; and global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with contractors such as Lockheed Martin and Northrop Grumman to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.